Phase 3 Osteoarthritis Trial, Recruiting NCT06549686 Sponsor: CellSeed Inc. Condition: Osteoarthritis
Back to Osteoarthritis

Phase 3 Osteoarthritis Trial, Recruiting

NCT06549686
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 20 to 79 years old at the time of signing consent forms
  • People who have been diagnosed with knee osteoarthritis rated at a specific severity level (Kellgren-Lawrence Grade 2 to 4) based on a knee X-ray
  • People whose knee condition is suitable for a type of bone surgery called proximal tibial osteotomy, meaning the knee can bend to at least 120 degrees and straighten to within 5 degrees of fully straight
  • People who have cartilage damage on certain parts of the knee joint, where each damaged area is at least 4 cm² in size
  • People with multiple areas of cartilage damage where the total damaged area is no larger than 21 cm²
  • People with a Body Mass Index (a measure of body weight relative to height) below 30
  • People who do not have ligament injuries or significant meniscus (cartilage cushion) injuries in the target knee that require surgical repair beyond minor removal
  • People with no history of certain previous knee procedures in the target knee, including ligament reconstruction, meniscus stitching, full meniscus removal, bone marrow stimulation, or treatment with regenerative medicine, cell, or gene therapy products
  • People who have not received hyaluronic acid injections or strong (opioid) pain medications in the target knee within the past month
  • People who have not received steroid injections or immune-suppressing medications in the target knee within the past 3 months
  • People who have not had platelet-rich plasma (PRP) therapy within the past 6 months
  • People who are non-smokers, or smokers who agree to stop smoking from 3 months before surgery until the bone has healed after the operation
  • People who give written voluntary agreement to take part in the study

Who may not be able to join:

  • People who need surgery on the other (non-study) knee during the trial period
  • People with other health conditions that could interfere with having surgery under general anaesthetic or that could affect knee surgery
  • People with a whole-body inflammatory condition such as rheumatoid arthritis
  • People with an active infection anywhere in the body, such as a bacterial, fungal, or viral infection
  • People with serious conditions affecting the liver, kidneys, heart, lungs, blood, or metabolism, if the trial doctor considers these to make the person unsuitable
  • People who have been diagnosed with or are suspected of having cancer, or who have had cancer within the past 5 years
  • People with an uncontrolled mental health condition
  • People with poorly controlled diabetes (indicated by a blood sugar marker called HbA1c above 7.0%)
  • People with a current joint infection (septic arthritis) in the target knee
  • Women who are pregnant, breastfeeding, or who could become pregnant — unless strict contraception requirements set by the trial (using methods approved in Japan) are met (confirm with trial site for full details)
  • People who have taken part in another clinical trial within the past 6 months, are currently in another trial, or plan to join another trial at the same time
  • People with a known allergy to certain antibiotics (benzylpenicillin potassium, streptomycin sulfate, or amphotericin B)
  • People with a known allergy to products derived from cattle
  • People the trial doctor considers unsuitable for any other reason

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Manabu Ishizuka, CellSeed Inc.

Phone: +81-03-6380-7490

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
CellSeed Inc.
Registry
ClinicalTrials.gov
Start date
20 October 2023
Est. completion
31 December 2028

Where this trial is recruiting

🇯🇵 Japan

Primary endpoints

KOOS 4 score (The Knee injury and Osteoarthritis Outcome 4 score)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov